Pharmafile Logo
Pharmafocus logo
Advanced Search

Clovis Oncology

Showing 4 posts of 4 posts found.

Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

October 11, 2019
Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …

News

Clovis Oncology discontinue phase 2 bladder cancer trial

April 15, 2019
Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer

Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …

News
shutterstock_159488225

Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show

April 3, 2019
Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma

At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …

News
cancerstudy

FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge

April 11, 2016
AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib

Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024